kabutan

Cyfuse Biomedical K.K., The Current Fiscal Year Net Income Loss Widened in Downward Revision

Thu Nov 14, 2024 4:00 pm JST Earnings

4892 Cyfuse Biomedical K.K. 【J-GAAP】

Earnings Report

Cyfuse Biomedical K.K. <4892> [TSE-G] announced its financial results after the market closed on November 14th (16:00). The net loss (non-consolidated) for the cumulative third quarter of the fiscal year ending December 2024 (January to September) expanded to a loss of 664 million yen (compared to a loss of 534 million yen in the same period last year).

In addition, the full-year net income/loss has been revised downward from an expected loss of 727 million yen to a loss of 904 million yen (compared to a loss of 589 million yen in the previous period), indicating an expansion in the loss margin.

Based on the full-year plan announced by the company after the downward revision, our estimate of the net income/loss for the July to December period (second half) has been revised downward from an expected loss of 280 million yen to a loss of 457 million yen (compared to a loss of 225 million yen in the same period of the previous year), indicating an expansion in the loss margin.

In the most recent three-month period, from July to September (3Q), the net loss expanded to a loss of 217 million yen (compared to a loss of 170 million yen in the same period last year). The operating profit/loss margin drastically worsened from -1500.0% in the same period last year to -2825.0%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Sep, 2023 29 -528 -532 -534 -68.5 ー Nov 14, 2023 J-GAAP
Jan - Sep, 2024 26 -674 -662 -664 -82.8 ー Nov 14, 2024 J-GAAP
YoY -10.3% -27.7% -24.4% -24.3% -20.9%

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2024 Prev 587 -349 -279 -280 -34.4 0 Aug 14, 2024 J-GAAP
Jul - Dec, 2024 New 42 -478 -456 -457 -56.2 0 Nov 14, 2024 J-GAAP
Revision Rate -92.8% -37.0% -63.4% -63.2% -63.2%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2024 Prev 605 -797 -724 -727 -89.4 0 Feb 14, 2024 J-GAAP
Dec, 2024 New 60 -926 -901 -904 -111.1 0 Nov 14, 2024 J-GAAP
Revision Rate -90.1% -16.2% -24.4% -24.3% -24.3%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2023 43 -334 -224 -225 -28.8 0 Feb 14, 2024 J-GAAP
Jul - Dec, 2024 Guidance 42 -478 -456 -457 -56.2 0 Nov 14, 2024 J-GAAP
YoY -2.3% -43.1% -103.6% -103.1% -95.0%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2022 374 -425 -433 -473 -178.1 0 Feb 14, 2023 J-GAAP
Dec, 2023 61 -697 -586 -589 -75.4 0 Feb 14, 2024 J-GAAP
Dec, 2024 Guidance 60 -926 -901 -904 -111.1 0 Nov 14, 2024 J-GAAP
YoY -1.6% -32.9% -53.8% -53.5% -47.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 11 -165 -170 -170 -21.8 -1,500.0 Nov 14, 2023 J-GAAP
Oct - Dec, 2023 32 -169 -54 -55 -7.0 -528.1 Feb 14, 2024 J-GAAP
Jan - Mar, 2024 10 -229 -223 -224 -28.4 -2,290.0 May 15, 2024 J-GAAP
Apr - Jun, 2024 8 -219 -222 -223 -28.0 -2,737.5 Aug 14, 2024 J-GAAP
Jul - Sep, 2024 8 -226 -217 -217 -27.1 -2,825.0 Nov 14, 2024 J-GAAP
YoY -27.3% -37.0% -27.6% -27.6% -24.1%

Related Articles